X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with J.B.Chemicals - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA J.B.CHEMICALS AJANTA PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 24.7 14.8 166.6% View Chart
P/BV x 10.2 2.3 434.3% View Chart
Dividend Yield % 0.6 0.2 356.6%  

Financials

 AJANTA PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
J.B.CHEMICALS
Mar-16
AJANTA PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,720318 540.7%   
Low Rs1,103200 552.9%   
Sales per share (Unadj.) Rs194.6148.0 131.5%  
Earnings per share (Unadj.) Rs45.219.1 236.9%  
Cash flow per share (Unadj.) Rs50.323.9 210.0%  
Dividends per share (Unadj.) Rs8.000.50 1,600.0%  
Dividend yield (eoy) %0.60.2 293.4%  
Book value per share (Unadj.) Rs132.0128.9 102.4%  
Shares outstanding (eoy) m88.7784.82 104.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.31.7 414.7%   
Avg P/E ratio x31.213.6 230.2%  
P/CF ratio (eoy) x28.110.8 259.7%  
Price / Book Value ratio x10.72.0 532.7%  
Dividend payout %17.72.6 675.3%   
Avg Mkt Cap Rs m125,29921,951 570.8%   
No. of employees `000NA2.7 0.0%   
Total wages/salary Rs m2,5701,841 139.6%   
Avg. sales/employee Rs ThNM4,590.9-  
Avg. wages/employee Rs ThNM673.4-  
Avg. net profit/employee Rs ThNM592.1-  
INCOME DATA
Net Sales Rs m17,27512,551 137.6%  
Other income Rs m166542 30.7%   
Total revenues Rs m17,44213,093 133.2%   
Gross profit Rs m5,8072,055 282.6%  
Depreciation Rs m451412 109.3%   
Interest Rs m4996 51.1%   
Profit before tax Rs m5,4742,088 262.1%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,460469 311.2%   
Profit after tax Rs m4,0141,619 248.0%  
Gross profit margin %33.616.4 205.3%  
Effective tax rate %26.722.5 118.7%   
Net profit margin %23.212.9 180.2%  
BALANCE SHEET DATA
Current assets Rs m7,6397,778 98.2%   
Current liabilities Rs m2,7154,358 62.3%   
Net working cap to sales %28.527.2 104.6%  
Current ratio x2.81.8 157.7%  
Inventory Days Days4355 79.1%  
Debtors Days Days7980 98.3%  
Net fixed assets Rs m6,9145,713 121.0%   
Share capital Rs m177170 104.3%   
"Free" reserves Rs m11,44210,547 108.5%   
Net worth Rs m11,72110,937 107.2%   
Long term debt Rs m1490-   
Total assets Rs m14,81415,574 95.1%  
Interest coverage x112.922.8 494.9%   
Debt to equity ratio x00-  
Sales to assets ratio x1.20.8 144.7%   
Return on assets %27.411.0 249.1%  
Return on equity %34.214.8 231.4%  
Return on capital %46.520.0 233.1%  
Exports to sales %55.148.7 113.2%   
Imports to sales %6.07.1 84.8%   
Exports (fob) Rs m9,5276,115 155.8%   
Imports (cif) Rs m1,038889 116.8%   
Fx inflow Rs m10,4226,169 168.9%   
Fx outflow Rs m1,6781,285 130.6%   
Net fx Rs m8,7444,884 179.0%   
CASH FLOW
From Operations Rs m3,2641,397 233.7%  
From Investments Rs m-2,093-320 653.4%  
From Financial Activity Rs m-1,186-1,196 99.2%  
Net Cashflow Rs m-15-102 14.5%  

Share Holding

Indian Promoters % 73.8 55.4 133.2%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 1.6 3.4 45.7%  
FIIs % 7.6 3.9 194.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 37.0 45.9%  
Shareholders   20,968 30,437 68.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   VENUS REMEDIES  SHASUN PHARMA  PFIZER  FDC LTD.  ORCHID PHARMA LTD  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Feb 21, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS